BioVieBIVI
Market Cap: $15.2M
About: BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Employees: 18
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
4% less funds holding
Funds holding: 51 [Q1] → 49 (-2) [Q2]
4.97% less ownership
Funds ownership: 12.25% [Q1] → 7.28% (-4.97%) [Q2]
13% less call options, than puts
Call options by funds: $14K | Put options by funds: $16K
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
50% less capital invested
Capital invested by funds: $3.56M [Q1] → $1.78M (-$1.77M) [Q2]
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
ThinkEquity Ashok Kumar 22% 1-year accuracy 2 / 9 met price target | 1,105%upside $30 | Buy Initiated | 1 Jul 2024 |